{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:30:48Z","timestamp":1792218648387,"version":"4.4.0"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40263-025-01182-8","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T10:02:23Z","timestamp":1743847343000},"page":"545-564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7689-2533","authenticated-orcid":false,"given":"Bruce A. C.","family":"Cree","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"3","key":"1182_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ana.21363","volume":"63","author":"A Bar-Or","year":"2008","unstructured":"Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395\u2013400. https:\/\/doi.org\/10.1002\/ana.21363.","journal-title":"Ann Neurol"},{"issue":"7","key":"1182_CR2","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"BA Cree","year":"2005","unstructured":"Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64(7):1270\u20132. https:\/\/doi.org\/10.1212\/01.WNL.0000159399.81861.D5.","journal-title":"Neurology"},{"issue":"1\u20132","key":"1182_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","volume":"180","author":"AH Cross","year":"2006","unstructured":"Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180(1\u20132):63\u201370. https:\/\/doi.org\/10.1016\/j.jneuroim.2006.06.029.","journal-title":"J Neuroimmunol"},{"issue":"7","key":"1182_CR4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676\u201388. https:\/\/doi.org\/10.1056\/NEJMoa0706383.","journal-title":"N Engl J Med"},{"issue":"11","key":"1182_CR5","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"A Jacob","year":"2008","unstructured":"Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443\u20138. https:\/\/doi.org\/10.1001\/archneur.65.11.noc80069.","journal-title":"Arch Neurol"},{"issue":"3","key":"1182_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1601277.","journal-title":"N Engl J Med"},{"key":"1182_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205584","author":"S Hauser","year":"2024","unstructured":"Hauser S, Kappos K, Filippi M, et al. 10 years of ocrelizumab treatment in multiple sclerosis: long-term efficacy and safety clinical trial data. Neurolpgy. 2024. https:\/\/doi.org\/10.1212\/WNL.0000000000205584.","journal-title":"Neurolpgy"},{"issue":"3","key":"1182_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","volume":"82","author":"YN Lamb","year":"2022","unstructured":"Lamb YN. Ocrelizumab: a review in multiple sclerosis. Drugs. 2022;82(3):323\u201334. https:\/\/doi.org\/10.1007\/s40265-022-01672-9.","journal-title":"Drugs"},{"key":"1182_CR9","unstructured":"KESIMPTA (ofatumumab). Prescribing information. Novartis; 2024. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/kesimpta.pdf. Accessed 6 Mar 2025."},{"key":"1182_CR10","doi-asserted-by":"publisher","first-page":"1004795","DOI":"10.3389\/fimmu.2023.1004795","volume":"14","author":"J de Seze","year":"2023","unstructured":"de Seze J, Maillart E, Gueguen A, et al. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Front Immunol. 2023;14:1004795. https:\/\/doi.org\/10.3389\/fimmu.2023.1004795.","journal-title":"Front Immunol"},{"key":"1182_CR11","unstructured":"BRIUMVI (ublituximab-xiiy). Prescribing information. TG Therapeutics; 2024. https:\/\/www.tgtherapeutics.com\/label-prescribing-info\/uspi-briumvi.pdf. Accessed 6 Mar 2025."},{"issue":"2","key":"1182_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/eji.202048665","volume":"51","author":"CC Hsiao","year":"2021","unstructured":"Hsiao CC, Fransen NL, van den Bosch AMR, et al. White matter lesions in multiple sclerosis are enriched for CD20(dim) CD8(+) tissue-resident memory T cells. Eur J Immunol. 2021;51(2):483\u20136. https:\/\/doi.org\/10.1002\/eji.202048665.","journal-title":"Eur J Immunol"},{"issue":"2","key":"1182_CR13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/cyto.990140212","volume":"14","author":"LE Hultin","year":"1993","unstructured":"Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry. 1993;14(2):196\u2013204. https:\/\/doi.org\/10.1002\/cyto.990140212.","journal-title":"Cytometry"},{"issue":"6","key":"1182_CR14","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova G, Mraz M. The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494\u2013506. https:\/\/doi.org\/10.3324\/haematol.2019.243543.","journal-title":"Haematologica"},{"issue":"10\u201311","key":"1182_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00011-022-01622-x","volume":"71","author":"AYS Lee","year":"2022","unstructured":"Lee AYS. CD20(+) T cells: an emerging T cell subset in human pathology. Inflamm Res. 2022;71(10\u201311):1181\u20139. https:\/\/doi.org\/10.1007\/s00011-022-01622-x.","journal-title":"Inflamm Res"},{"issue":"4","key":"1182_CR16","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","volume":"271","author":"SR Delgado","year":"2024","unstructured":"Delgado SR, Faissner S, Linker RA, Rammohan K. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. J Neurol. 2024;271(4):1515\u201335. https:\/\/doi.org\/10.1007\/s00415-023-12007-3.","journal-title":"J Neurol"},{"key":"1182_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000082102","volume":"8","author":"MS Cragg","year":"2005","unstructured":"Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140\u201374. https:\/\/doi.org\/10.1159\/000082102.","journal-title":"Curr Dir Autoimmun"},{"issue":"3","key":"1182_CR18","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","volume":"269","author":"M Margoni","year":"2022","unstructured":"Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022;269(3):1316\u201334. https:\/\/doi.org\/10.1007\/s00415-021-10744-x.","journal-title":"J Neurol"},{"issue":"1","key":"1182_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","volume":"177","author":"JL Teeling","year":"2006","unstructured":"Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362\u201371. https:\/\/doi.org\/10.4049\/jimmunol.177.1.362.","journal-title":"J Immunol"},{"key":"1182_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102787","volume":"49","author":"KR Cotchett","year":"2021","unstructured":"Cotchett KR, Dittel BN, Obeidat AZ. Comparison of the efficacy and safety of anti-CD20 B cells depleting drugs in multiple sclerosis. Mult Scler Relat Disord. 2021;49: 102787. https:\/\/doi.org\/10.1016\/j.msard.2021.102787.","journal-title":"Mult Scler Relat Disord."},{"issue":"2","key":"1182_CR21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4049\/jimmunol.1400118","volume":"193","author":"A Palanichamy","year":"2014","unstructured":"Palanichamy A, Jahn S, Nickles D, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193(2):580\u20136. https:\/\/doi.org\/10.4049\/jimmunol.1400118.","journal-title":"J Immunol"},{"issue":"3","key":"1182_CR22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2207291120","volume":"120","author":"K Shinoda","year":"2023","unstructured":"Shinoda K, Li R, Rezk A, et al. Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. Proc Natl Acad Sci U S A. 2023;120(3): e2207291120. https:\/\/doi.org\/10.1073\/pnas.2207291120.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1182_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200004","volume":"9","author":"MR von Essen","year":"2022","unstructured":"von Essen MR, Hansen RH, Hojgaard C, Ammitzboll C, Wiendl H, Sellebjerg F. Ofatumumab modulates inflammatory T cell responses and migratory potential in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9(4): e200004. https:\/\/doi.org\/10.1212\/NXI.0000000000200004.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"4","key":"1182_CR24","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.4049\/jimmunol.1600089","volume":"197","author":"E Schuh","year":"2016","unstructured":"Schuh E, Berer K, Mulazzani M, et al. Features of human CD3+CD20+ T cells. J Immunol. 2016;197(4):1111\u20137. https:\/\/doi.org\/10.4049\/jimmunol.1600089.","journal-title":"J Immunol"},{"issue":"5","key":"1182_CR25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.msard.2014.06.001","volume":"3","author":"JE Holley","year":"2014","unstructured":"Holley JE, Bremer E, Kendall AC, et al. CD20+inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination. Mult Scler Relat Disord. 2014;3(5):650\u20138. https:\/\/doi.org\/10.1016\/j.msard.2014.06.001.","journal-title":"Mult Scler Relat Disord."},{"issue":"51","key":"1182_CR26","doi-asserted-by":"publisher","first-page":"25800","DOI":"10.1073\/pnas.1915309116","volume":"116","author":"JJ Sabatino Jr","year":"2019","unstructured":"Sabatino JJ Jr, Wilson MR, Calabresi PA, Hauser SL, Schneck JP, Zamvil SS. Anti-CD20 therapy depletes activated myelin-specific CD8(+) T cells in multiple sclerosis. Proc Natl Acad Sci U S A. 2019;116(51):25800\u20137. https:\/\/doi.org\/10.1073\/pnas.1915309116.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"638","key":"1182_CR27","doi-asserted-by":"publisher","first-page":"eabi4632","DOI":"10.1126\/scitranslmed.abi4632","volume":"14","author":"J Ochs","year":"2022","unstructured":"Ochs J, Nissimov N, Torke S, et al. Proinflammatory CD20(+) T cells contribute to CNS-directed autoimmunity. Sci Transl Med. 2022;14(638):eabi4632. https:\/\/doi.org\/10.1126\/scitranslmed.abi4632.","journal-title":"Sci Transl Med."},{"issue":"1","key":"1182_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/brain\/awy301","volume":"142","author":"MR von Essen","year":"2019","unstructured":"von Essen MR, Ammitzboll C, Hansen RH, et al. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. Brain. 2019;142(1):120\u201332. https:\/\/doi.org\/10.1093\/brain\/awy301.","journal-title":"Brain"},{"issue":"5","key":"1182_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200140","volume":"10","author":"MR von Essen","year":"2023","unstructured":"von Essen MR, Talbot J, Hansen RHH, et al. Intrathecal CD8(+)CD20(+) T cells in primary progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(5): e200140. https:\/\/doi.org\/10.1212\/NXI.0000000000200140.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"2","key":"1182_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/1352458517740641","volume":"25","author":"MA Agius","year":"2019","unstructured":"Agius MA, Klodowska-Duda G, Maciejowski M, et al. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler. 2019;25(2):235\u201345. https:\/\/doi.org\/10.1177\/1352458517740641.","journal-title":"Mult Scler"},{"issue":"10206","key":"1182_CR31","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(19)31817-3.","journal-title":"Lancet"},{"issue":"13","key":"1182_CR32","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.166137","volume":"8","author":"JS Boyles","year":"2023","unstructured":"Boyles JS, Sadowski D, Potter S, et al. A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases. JCI Insight. 2023;8(13): e166137. https:\/\/doi.org\/10.1172\/jci.insight.166137.","journal-title":"JCI Insight."},{"issue":"7","key":"1182_CR33","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1177\/13524585221147635","volume":"29","author":"G Abbadessa","year":"2023","unstructured":"Abbadessa G, Miele G, Maida E, et al. Immunomodulatory effects of ocrelizumab and candidate biomarkers for monitoring treatment response in multiple sclerosis. Mult Scler. 2023;29(7):779\u201388. https:\/\/doi.org\/10.1177\/13524585221147635.","journal-title":"Mult Scler"},{"issue":"2","key":"1182_CR34","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200084","volume":"10","author":"A Mathias","year":"2023","unstructured":"Mathias A, Pantazou V, Perriot S, et al. Ocrelizumab impairs the phenotype and function of memory CD8(+) T cells: a 1-year longitudinal study in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(2): e200084. https:\/\/doi.org\/10.1212\/NXI.0000000000200084.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"3","key":"1182_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200091","volume":"10","author":"A Garcia","year":"2023","unstructured":"Garcia A, Dugast E, Shah S, et al. Immune profiling reveals the T-cell effect of ocrelizumab in early relapsing-remitting multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(3): e200091. https:\/\/doi.org\/10.1212\/NXI.0000000000200091.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"2","key":"1182_CR36","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000940","volume":"8","author":"JI Fernandez-Velasco","year":"2021","unstructured":"Fernandez-Velasco JI, Kuhle J, Monreal E, et al. Effect of ocrelizumab in blood leukocytes of patients with primary progressive MS. Neurol Neuroimmunol Neuroinflamm. 2021;8(2): e940. https:\/\/doi.org\/10.1212\/NXI.0000000000000940.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"4","key":"1182_CR37","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200250","volume":"11","author":"G Abbadessa","year":"2024","unstructured":"Abbadessa G, Lepore MT, Bruzzaniti S, et al. Ocrelizumab alters cytotoxic lymphocyte function while reducing EBV-specific CD8(+) T-cell proliferation in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2024;11(4): e200250. https:\/\/doi.org\/10.1212\/NXI.0000000000200250.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"3","key":"1182_CR38","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/brain\/awae244","volume":"148","author":"T Schneider-Hohendorf","year":"2024","unstructured":"Schneider-Hohendorf T, Wunsch C, Falk S, et al. Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation. Brain. 2024;148(3):933\u201340. https:\/\/doi.org\/10.1093\/brain\/awae244.","journal-title":"Brain"},{"key":"1182_CR39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fonc.2018.00163","volume":"8","author":"TM Pierpont","year":"2018","unstructured":"Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab\u2014the world\u2019s first oncology monoclonal antibody therapy. Front Oncol. 2018;8:163. https:\/\/doi.org\/10.3389\/fonc.2018.00163.","journal-title":"Front Oncol"},{"issue":"1","key":"1182_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40744-019-00183-6","volume":"7","author":"P Emery","year":"2020","unstructured":"Emery P, Furst DE, Kirchner P, Melega S, Lacey S, Lehane PB. Risk of malignancies in patients with rheumatoid arthritis treated with rituximab: analyses of global postmarketing safety data and long-term clinical trial data. Rheumatol Ther. 2020;7(1):121\u201331. https:\/\/doi.org\/10.1007\/s40744-019-00183-6.","journal-title":"Rheumatol Ther."},{"key":"1182_CR41","unstructured":"RITUXAN (rituximab). Prescribing information. Genentech; 2021. https:\/\/www.gene.com\/download\/pdf\/rituxan_prescribing.pdf. Accessed 6 Mar 2025."},{"key":"1182_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661882","volume":"12","author":"S Brancati","year":"2021","unstructured":"Brancati S, Gozzo L, Longo L, Vitale DC, Drago F. Rituximab in multiple sclerosis: are we ready for regulatory approval? Front Immunol. 2021;12: 661882. https:\/\/doi.org\/10.3389\/fimmu.2021.661882.","journal-title":"Front Immunol"},{"key":"1182_CR43","unstructured":"Hanif N, Anwer F. Rituximab. In: StatPearls [Internet]. Treasure Island (FL, USA): StatPearls Publishing; 2025. Accessed 6 Mar 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564374\/"},{"issue":"10","key":"1182_CR44","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1001\/archneur.62.10.1620","volume":"62","author":"O St\u00fcve","year":"2005","unstructured":"St\u00fcve O, Cepok S, Elias B, et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol. 2005;62(10):1620\u20133. https:\/\/doi.org\/10.1001\/archneur.62.10.1620.","journal-title":"Arch Neurol"},{"issue":"4","key":"1182_CR45","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O\u2019Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460\u201371. https:\/\/doi.org\/10.1002\/ana.21867.","journal-title":"Ann Neurol"},{"issue":"1","key":"1182_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T K\u00fcmpfel","year":"2024","unstructured":"K\u00fcmpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u2014revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2024;271(1):141\u201376. https:\/\/doi.org\/10.1007\/s00415-023-11910-z.","journal-title":"J Neurol"},{"issue":"4","key":"1182_CR47","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/s1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298\u2013306. https:\/\/doi.org\/10.1016\/s1474-4422(20)30066-1.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1182_CR48","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","volume":"2","author":"FA Harding","year":"2010","unstructured":"Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2(3):256\u201365. https:\/\/doi.org\/10.4161\/mabs.2.3.11641.","journal-title":"MAbs"},{"issue":"1","key":"1182_CR49","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1038\/s41467-022-29421-2","volume":"13","author":"H Satofuka","year":"2022","unstructured":"Satofuka H, Abe S, Moriwaki T, et al. Efficient human-like antibody repertoire and hybridoma production in trans-chromosomic mice carrying megabase-sized human immunoglobulin loci. Nat Commun. 2022;13(1):1841. https:\/\/doi.org\/10.1038\/s41467-022-29421-2.","journal-title":"Nat Commun"},{"key":"1182_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/pgpm.s6840","volume":"3","author":"TS Lin","year":"2010","unstructured":"Lin TS. Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmgenomics Pers Med. 2010;3:51\u20139. https:\/\/doi.org\/10.2147\/pgpm.s6840.","journal-title":"Pharmgenomics Pers Med."},{"issue":"6","key":"1182_CR51","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","volume":"104","author":"JL Teeling","year":"2004","unstructured":"Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104(6):1793\u2013800. https:\/\/doi.org\/10.1182\/blood-2004-01-0039.","journal-title":"Blood"},{"issue":"3","key":"1182_CR52","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/1352458520918375","volume":"27","author":"E Fox","year":"2021","unstructured":"Fox E, Lovett-Racke AE, Gormley M, et al. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis. Mult Scler. 2021;27(3):420\u20139. https:\/\/doi.org\/10.1177\/1352458520918375.","journal-title":"Mult Scler"},{"issue":"1","key":"1182_CR53","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","volume":"5","author":"C Klein","year":"2013","unstructured":"Klein C, Lammens A, Schafer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5(1):22\u201333. https:\/\/doi.org\/10.4161\/mabs.22771.","journal-title":"MAbs"},{"issue":"9","key":"1182_CR54","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.3390\/jcm12093271","volume":"12","author":"O Pizano-Martinez","year":"2023","unstructured":"Pizano-Martinez O, Mendieta-Condado E, V\u00e1zquez-Del Mercado M, et al. Anti-drug antibodies in the biological therapy of autoimmune rheumatic diseases. J Clin Med. 2023;12(9):3271. https:\/\/doi.org\/10.3390\/jcm12093271.","journal-title":"J Clin Med"},{"key":"1182_CR55","unstructured":"Alvarez E, Steinman L, Fox EJ, et al. Neutralizing antibodies and antidrug antibodies in the ublituximab phase 3 ULTIMATE I and II studies in relapsing multiple sclerosis. In: Presented at the 2022 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum; 24-26 Feb 2022; West Palm Beach, FL, USA. Poster P103."},{"issue":"9","key":"1182_CR56","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1177\/1352458517720044","volume":"24","author":"N Dunn","year":"2018","unstructured":"Dunn N, Juto A, Ryner M, et al. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler. 2018;24(9):1224\u201333. https:\/\/doi.org\/10.1177\/1352458517720044.","journal-title":"Mult Scler"},{"key":"1182_CR57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/DDDT.S4378","volume":"3","author":"A Natsume","year":"2009","unstructured":"Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Des Devel Ther. 2009;3:7\u201316. https:\/\/doi.org\/10.2147\/DDDT.S4378.","journal-title":"Drug Des Devel Ther."},{"issue":"21\u201322","key":"1182_CR58","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.drudis.2007.08.009","volume":"12","author":"JR Desjarlais","year":"2007","unstructured":"Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer\u2019s perspective. Drug Discov Today. 2007;12(21\u201322):898\u2013910. https:\/\/doi.org\/10.1016\/j.drudis.2007.08.009.","journal-title":"Drug Discov Today"},{"issue":"17","key":"1182_CR59","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1097\/QAD.0000000000000444","volume":"28","author":"AW Chung","year":"2014","unstructured":"Chung AW, Crispin M, Pritchard L, et al. Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. AIDS. 2014;28(17):2523\u201330. https:\/\/doi.org\/10.1097\/QAD.0000000000000444.","journal-title":"AIDS"},{"issue":"3","key":"1182_CR60","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10616-011-9377-2","volume":"64","author":"Y Konno","year":"2012","unstructured":"Konno Y, Kobayashi Y, Takahashi K, et al. Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity. Cytotechnology. 2012;64(3):249\u201365. https:\/\/doi.org\/10.1007\/s10616-011-9377-2.","journal-title":"Cytotechnology"},{"key":"1182_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100891","volume":"79","author":"T \u0160tambuk","year":"2021","unstructured":"\u0160tambuk T, Klasic M, Zoldos V, Lauc G. N-glycans as functional effectors of genetic and epigenetic disease risk. Mol Aspects Med. 2021;79: 100891. https:\/\/doi.org\/10.1016\/j.mam.2020.100891.","journal-title":"Mol Aspects Med"},{"issue":"31","key":"1182_CR62","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1073\/pnas.1108455108","volume":"108","author":"C Ferrara","year":"2011","unstructured":"Ferrara C, Grau S, Jager C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A. 2011;108(31):12669\u201374. https:\/\/doi.org\/10.1073\/pnas.1108455108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1182_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100826","volume":"297","author":"Y Sun","year":"2021","unstructured":"Sun Y, Izadi S, Callahan M, Deperalta G, Wecksler AT. Antibody-receptor interactions mediate antibody-dependent cellular cytotoxicity. J Biol Chem. 2021;297(1): 100826. https:\/\/doi.org\/10.1016\/j.jbc.2021.100826.","journal-title":"J Biol Chem"},{"issue":"19","key":"1182_CR64","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388(19):1739\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2213093.","journal-title":"N Engl J Med"},{"issue":"22","key":"1182_CR65","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u04e7ssner","year":"2010","unstructured":"M\u04e7ssner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393\u2013402. https:\/\/doi.org\/10.1182\/blood-2009-06-225979.","journal-title":"Blood"},{"issue":"9","key":"1182_CR66","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","volume":"76","author":"ED Deeks","year":"2016","unstructured":"Deeks ED. Venetoclax: first global approval. Drugs. 2016;76(9):979\u201387. https:\/\/doi.org\/10.1007\/s40265-016-0596-x.","journal-title":"Drugs"},{"issue":"14","key":"1182_CR67","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1614598.","journal-title":"N Engl J Med"},{"issue":"2","key":"1182_CR68","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00262-009-0746-z","volume":"59","author":"PM Cardarelli","year":"2010","unstructured":"Cardarelli PM, Rao-Naik C, Chen S, et al. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2010;59(2):257\u201365. https:\/\/doi.org\/10.1007\/s00262-009-0746-z.","journal-title":"Cancer Immunol Immunother"},{"key":"1182_CR69","unstructured":"UPLIZNA (inebilizumab-cdon). Prescribing information. Horizon Therapeutics; 2021. https:\/\/www.hzndocs.com\/Uplizna-Prescribing-Information.pdf. Accessed 6 Mar 2025."},{"key":"1182_CR70","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.intimp.2016.04.035","volume":"36","author":"S Gallagher","year":"2016","unstructured":"Gallagher S, Turman S, Yusuf I, et al. Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice. Int Immunopharmacol. 2016;36:205\u201312. https:\/\/doi.org\/10.1016\/j.intimp.2016.04.035.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1182_CR71","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1124\/jpet.110.168062","volume":"335","author":"R Herbst","year":"2010","unstructured":"Herbst R, Wang Y, Gallagher S, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010;335(1):213\u201322. https:\/\/doi.org\/10.1124\/jpet.110.168062.","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"1182_CR72","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","volume":"80","author":"JE Frampton","year":"2020","unstructured":"Frampton JE. Inebilizumab: first approval. Drugs. 2020;80(12):1259\u201364. https:\/\/doi.org\/10.1007\/s40265-020-01370-4.","journal-title":"Drugs"},{"issue":"6","key":"1182_CR73","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/j.1365-2141.2007.06974.x","volume":"140","author":"C de Romeuf","year":"2008","unstructured":"de Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA\/CD16. Br J Haematol. 2008;140(6):635\u201343. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06974.x.","journal-title":"Br J Haematol"},{"key":"1182_CR74","unstructured":"Foley JF, Alvarez E, Fox EJ, Miskin HP, Lee L, Steinman L. Ublituximab, a novel, glycoengineered anti-CD20 monoclonal antibody (mAb), demonstrates enhanced antibody dependent cellular cytolysis (ADCC) relative to other anti CD20 mAbs. In: Presented at the 75th American Academy of Neurology (AAN) Annual Meeting; 22-27 Apr 2023; Boston, MA, USA. Poster P7.011."},{"issue":"9","key":"1182_CR75","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1093\/annonc\/mdq027","volume":"21","author":"F Morschhauser","year":"2010","unstructured":"Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I\/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed\/refractory follicular lymphoma. Ann Oncol. 2010;21(9):1870\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdq027.","journal-title":"Ann Oncol"},{"issue":"1","key":"1182_CR76","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.12341","volume":"268","author":"CE Hargreaves","year":"2015","unstructured":"Hargreaves CE, Rose-Zerilli MJ, Machado LR, et al. Fc\u03b3 receptors: genetic variation, function, and disease. Immunol Rev. 2015;268(1):6\u201324. https:\/\/doi.org\/10.1111\/imr.12341.","journal-title":"Immunol Rev"},{"issue":"17","key":"1182_CR77","doi-asserted-by":"publisher","first-page":"9489","DOI":"10.3390\/ijms22179489","volume":"22","author":"J Kim","year":"2021","unstructured":"Kim J, Lee JY, Kim HG, Kwak MW, Kang TH. Fc receptor variants and disease: a crucial factor to consider in the antibody therapeutics in clinic. Int J Mol Sci. 2021;22(17):9489. https:\/\/doi.org\/10.3390\/ijms22179489.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1182_CR78","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","volume":"90","author":"HR Koene","year":"1997","unstructured":"Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype. Blood. 1997;90(3):1109\u201314. https:\/\/doi.org\/10.1182\/blood.V90.3.1109.","journal-title":"Blood"},{"issue":"4","key":"1182_CR79","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1007\/s13311-020-00950-2","volume":"17","author":"M Zhong","year":"2020","unstructured":"Zhong M, van der Walt A, Campagna MP, Stankovich J, Butzkueven H, Jokubaitis V. The pharmacogenetics of rituximab: potential implications for anti-CD20 therapies in multiple sclerosis. Neurotherapeutics. 2020;17(4):1768\u201384. https:\/\/doi.org\/10.1007\/s13311-020-00950-2.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1182_CR80","doi-asserted-by":"publisher","first-page":"15983","DOI":"10.1038\/s41598-018-34258-1","volume":"8","author":"NM Mahaweni","year":"2018","unstructured":"Mahaweni NM, Olieslagers TI, Rivas IO, et al. A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism. Sci Rep. 2018;8(1):15983. https:\/\/doi.org\/10.1038\/s41598-018-34258-1.","journal-title":"Sci Rep"},{"issue":"9","key":"1182_CR81","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","volume":"72","author":"SH Kim","year":"2015","unstructured":"Kim SH, Jeong IH, Hyun JW, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72(9):989\u201395. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1276.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1182_CR82","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1136\/annrheumdis-2012-202435","volume":"73","author":"L Quartuccio","year":"2014","unstructured":"Quartuccio L, Fabris M, Pontarini E, et al. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann Rheum Dis. 2014;73(4):716\u201321. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202435.","journal-title":"Ann Rheum Dis"},{"key":"1182_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104343","volume":"86","author":"JI Robinson","year":"2022","unstructured":"Robinson JI, Md Yusof MY, Davies V, et al. Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity. EBioMedicine. 2022;86: 104343. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104343.","journal-title":"EBioMedicine"},{"key":"1182_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.926289","volume":"12","author":"JJ Mata-Molanes","year":"2022","unstructured":"Mata-Molanes JJ, Rebollo-Liceaga J, Martinez-Navarro EM, et al. Relevance of Fc gamma receptor polymorphisms in cancer therapy with monoclonal antibodies. Front Oncol. 2022;12: 926289. https:\/\/doi.org\/10.3389\/fonc.2022.926289.","journal-title":"Front Oncol"},{"key":"1182_CR85","unstructured":"Abbadessa G, Miele G, Benedetti R, et al. Influence of FCGR3A-V158F polymorphism on the therapeutic response to ocrelizumab in patients with relapsing multiple sclerosis. In: Presented at the Joint ECTRIMS-ACTRIMS Meeting: MSMilan2023; 11-13 Oct 2023; Milan, Italy. Poster 1543."},{"issue":"12","key":"1182_CR86","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1002\/acn3.51911","volume":"10","author":"HJ Kim","year":"2023","unstructured":"Kim HJ, Aktas O, Patterson KR, et al. Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism. Ann Clin Transl Neurol. 2023;10(12):2413\u201320. https:\/\/doi.org\/10.1002\/acn3.51911.","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"1182_CR87","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1080\/21645515.2018.1508624","volume":"14","author":"JML Casan","year":"2018","unstructured":"Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother. 2018;14(12):2820\u201341. https:\/\/doi.org\/10.1080\/21645515.2018.1508624.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"1182_CR88","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/14737175.2017.1245616","volume":"17","author":"I Moreno Torres","year":"2017","unstructured":"Moreno Torres I, Garcia-Merino A. Anti-CD20 monoclonal antibodies in multiple sclerosis. Expert Rev Neurother. 2017;17(4):359\u201371. https:\/\/doi.org\/10.1080\/14737175.2017.1245616.","journal-title":"Expert Rev Neurother"},{"issue":"9","key":"1182_CR89","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40263-021-00843-8","volume":"35","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or A, O\u2019Brien SM, Sweeney ML, Fox EJ, Cohen JA. Clinical perspectives on the molecular and pharmacological attributes of anti-CD20 therapies for multiple sclerosis. CNS Drugs. 2021;35(9):985\u201397. https:\/\/doi.org\/10.1007\/s40263-021-00843-8.","journal-title":"CNS Drugs"},{"key":"1182_CR90","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-2407-9-58","volume":"9","author":"S Iida","year":"2009","unstructured":"Iida S, Kuni-Kamochi R, Mori K, et al. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer. 2009;9:58. https:\/\/doi.org\/10.1186\/1471-2407-9-58.","journal-title":"BMC Cancer"},{"issue":"5","key":"1182_CR91","doi-asserted-by":"publisher","first-page":"105","DOI":"10.21037\/atm.2019.01.42","volume":"7","author":"C Lo Nigro","year":"2019","unstructured":"Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. Ann Transl Med. 2019;7(5):105. https:\/\/doi.org\/10.21037\/atm.2019.01.42.","journal-title":"Ann Transl Med."},{"issue":"2","key":"1182_CR92","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1188\/10.CJON.E10-E21","volume":"14","author":"WH Vogel","year":"2010","unstructured":"Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14(2):E10-21. https:\/\/doi.org\/10.1188\/10.CJON.E10-E21.","journal-title":"Clin J Oncol Nurs"},{"issue":"7","key":"1182_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2015.14","volume":"4","author":"L Doessegger","year":"2015","unstructured":"Doessegger L, Banholzer ML. Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Transl Immunology. 2015;4(7): e39. https:\/\/doi.org\/10.1038\/cti.2015.14.","journal-title":"Clin Transl Immunology."},{"issue":"8","key":"1182_CR94","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman L, Fox E, Hartung HP, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2201904.","journal-title":"N Engl J Med"},{"issue":"8","key":"1182_CR95","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1600-6143.2004.00502.x","volume":"4","author":"A Agarwal","year":"2004","unstructured":"Agarwal A, Vieira CA, Book BK, Sidner RA, Fineberg NS, Pescovitz MD. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant. 2004;4(8):1357\u201360. https:\/\/doi.org\/10.1111\/j.1600-6143.2004.00502.x.","journal-title":"Am J Transplant"},{"issue":"8","key":"1182_CR96","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","volume":"19","author":"JC Byrd","year":"2001","unstructured":"Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19(8):2153\u201364. https:\/\/doi.org\/10.1200\/JCO.2001.19.8.2153.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1182_CR97","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1182\/blood-2015-09-670802","volume":"126","author":"CL Freeman","year":"2015","unstructured":"Freeman CL, Morschhauser F, Sehn L, et al. Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood. 2015;126(24):2646\u20139. https:\/\/doi.org\/10.1182\/blood-2015-09-670802.","journal-title":"Blood"},{"issue":"7","key":"1182_CR98","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","volume":"94","author":"U Winkler","year":"1999","unstructured":"Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94(7):2217\u201324. https:\/\/doi.org\/10.1182\/blood.V94.7.2217.419k02_2217_2224.","journal-title":"Blood"},{"issue":"2","key":"1182_CR99","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.molimm.2014.06.038","volume":"61","author":"J Szebeni","year":"2014","unstructured":"Szebeni J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol. 2014;61(2):163\u201373. https:\/\/doi.org\/10.1016\/j.molimm.2014.06.038.","journal-title":"Mol Immunol"},{"key":"1182_CR100","unstructured":"OCREVUS (ocrelizumab). Prescribing information. Genentech; 2024. https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf. Accessed 6 Mar 2025."},{"issue":"5","key":"1182_CR101","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","volume":"32","author":"B Bittner","year":"2018","unstructured":"Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425\u201340. https:\/\/doi.org\/10.1007\/s40259-018-0295-0.","journal-title":"BioDrugs"},{"key":"1182_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104246","volume":"68","author":"S El Mahdaoui","year":"2022","unstructured":"El Mahdaoui S, Romme Christensen J, Magyari M, Wandall-Holm MF, Sellebjerg F. Intravenous ofatumumab treatment of multiple sclerosis and related disorders: an observational study. Mult Scler Relat Disord. 2022;68: 104246. https:\/\/doi.org\/10.1016\/j.msard.2022.104246.","journal-title":"Mult Scler Relat Disord."},{"issue":"7","key":"1182_CR103","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1212\/wnl.0000000000000125","volume":"82","author":"PS Sorensen","year":"2014","unstructured":"Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014;82(7):573\u201381. https:\/\/doi.org\/10.1212\/wnl.0000000000000125.","journal-title":"Neurology"},{"issue":"4","key":"1182_CR104","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.4049\/jimmunol.180.4.2294","volume":"180","author":"T Tawara","year":"2008","unstructured":"Tawara T, Hasegawa K, Sugiura Y, et al. Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J Immunol. 2008;180(4):2294\u20138. https:\/\/doi.org\/10.4049\/jimmunol.180.4.2294.","journal-title":"J Immunol"},{"issue":"4","key":"1182_CR105","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","volume":"115","author":"LE van der Kolk","year":"2001","unstructured":"van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001;115(4):807\u201311. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.03166.x.","journal-title":"Br J Haematol"},{"issue":"6","key":"1182_CR106","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","volume":"33","author":"M Noris","year":"2013","unstructured":"Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. 2013;33(6):479\u201392. https:\/\/doi.org\/10.1016\/j.semnephrol.2013.08.001.","journal-title":"Semin Nephrol"},{"issue":"15","key":"1182_CR107","doi-asserted-by":"publisher","first-page":"8163","DOI":"10.3390\/ijerph18158163","volume":"18","author":"G Abbadessa","year":"2021","unstructured":"Abbadessa G, Miele G, Cavalla P, et al. CD19 cell count at baseline predicts B cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab. Int J Environ Res Public Health. 2021;18(15):8163. https:\/\/doi.org\/10.3390\/ijerph18158163.","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"1182_CR108","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1111\/bcp.14658","volume":"87","author":"E Gibiansky","year":"2021","unstructured":"Gibiansky E, Petry C, Mercier F, et al. Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol. 2021;87(6):2511\u201320. https:\/\/doi.org\/10.1111\/bcp.14658.","journal-title":"Br J Clin Pharmacol"},{"key":"1182_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102186","volume":"43","author":"E Signoriello","year":"2020","unstructured":"Signoriello E, Bonavita S, Di Pietro A, et al. BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab. Mult Scler Relat Disord. 2020;43: 102186. https:\/\/doi.org\/10.1016\/j.msard.2020.102186.","journal-title":"Mult Scler Relat Disord."},{"issue":"39","key":"1182_CR110","doi-asserted-by":"publisher","first-page":"9773","DOI":"10.1073\/pnas.1810470115","volume":"115","author":"D H\u00e4usler","year":"2018","unstructured":"H\u00e4usler D, H\u00e4usser-Kinzel S, Feldmann L, et al. Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease. Proc Natl Acad Sci U S A. 2018;115(39):9773\u20138. https:\/\/doi.org\/10.1073\/pnas.1810470115.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1182_CR111","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200094","volume":"10","author":"SL Hauser","year":"2023","unstructured":"Hauser SL, Bar-Or A, Weber MS, et al. Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(2): e200094. https:\/\/doi.org\/10.1212\/NXI.0000000000200094.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"5","key":"1182_CR112","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001035","volume":"8","author":"L Rolfes","year":"2021","unstructured":"Rolfes L, Pawlitzki M, Pfeuffer S, et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm. 2021;8(5): e1035. https:\/\/doi.org\/10.1212\/nxi.0000000000001035.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"6","key":"1182_CR113","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s13311-023-01446-5","volume":"20","author":"SA Freeman","year":"2023","unstructured":"Freeman SA, Lemarchant B, Alberto T, et al. Assessing sustained B-cell depletion and disease activity in a French multiple sclerosis cohort treated by long-term IV anti-CD20 antibody therapy. Neurotherapeutics. 2023;20(6):1707\u201322. https:\/\/doi.org\/10.1007\/s13311-023-01446-5.","journal-title":"Neurotherapeutics"},{"issue":"5","key":"1182_CR114","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200152","volume":"10","author":"R Claverie","year":"2023","unstructured":"Claverie R, Perriguey M, Rico A, et al. Efficacy of rituximab outlasts B-cell repopulation in multiple sclerosis: time to rethink dosing? Neurol Neuroimmunol Neuroinflamm. 2023;10(5): e200152. https:\/\/doi.org\/10.1212\/nxi.0000000000200152.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1182_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103287","volume":"56","author":"NK Sahi","year":"2021","unstructured":"Sahi NK, Abidi SMA, Salim O, Abraham R, Kalra S, Al-Araji A. Clinical impact of ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19(+) B-cell repopulation. Mult Scler Relat Disord. 2021;56: 103287. https:\/\/doi.org\/10.1016\/j.msard.2021.103287.","journal-title":"Mult Scler Relat Disord."},{"issue":"1","key":"1182_CR116","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12974-023-02900-z","volume":"20","author":"C Rodriguez-Mogeda","year":"2023","unstructured":"Rodriguez-Mogeda C, van Lierop Z, van der Pol SMA, et al. Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis. J Neuroinflammation. 2023;20(1):215. https:\/\/doi.org\/10.1186\/s12974-023-02900-z.","journal-title":"J Neuroinflammation"},{"key":"1182_CR117","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jim.2017.03.014","volume":"445","author":"J Dock","year":"2017","unstructured":"Dock J, Hultin L, Hultin P, et al. Human immune compartment comparisons: optimization of proliferative assays for blood and gut T lymphocytes. J Immunol Methods. 2017;445:77\u201387. https:\/\/doi.org\/10.1016\/j.jim.2017.03.014.","journal-title":"J Immunol Methods"},{"issue":"8","key":"1182_CR118","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41582-023-00838-7","volume":"19","author":"R Magliozzi","year":"2023","unstructured":"Magliozzi R, Howell OW, Calabrese M, Reynolds R. Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis. Nat Rev Neurol. 2023;19(8):461\u201376. https:\/\/doi.org\/10.1038\/s41582-023-00838-7.","journal-title":"Nat Rev Neurol"},{"issue":"Pt 4","key":"1182_CR119","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awm038","volume":"130","author":"R Magliozzi","year":"2007","unstructured":"Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130(Pt 4):1089\u2013104. https:\/\/doi.org\/10.1093\/brain\/awm038.","journal-title":"Brain"},{"issue":"4","key":"1182_CR120","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1309\/UXLE9RHL968TER7B","volume":"130","author":"AM Cioc","year":"2008","unstructured":"Cioc AM, Vanderwerf SM, Peterson BA, Robu VG, Forster CL, Pambuccian SE. Rituximab-induced changes in hematolymphoid tissues found at autopsy. Am J Clin Pathol. 2008;130(4):604\u201312. https:\/\/doi.org\/10.1309\/UXLE9RHL968TER7B.","journal-title":"Am J Clin Pathol"},{"issue":"Suppl 1","key":"1182_CR121","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1186\/ar3908","volume":"15 Suppl 1","author":"MJ Leandro","year":"2013","unstructured":"Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15 Suppl 1(Suppl 1):S3. https:\/\/doi.org\/10.1186\/ar3908.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"1182_CR122","doi-asserted-by":"publisher","first-page":"R123","DOI":"10.1186\/ar2789","volume":"11","author":"M Rehnberg","year":"2009","unstructured":"Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(4):R123. https:\/\/doi.org\/10.1186\/ar2789.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"1182_CR123","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/archneurol.2010.99","volume":"67","author":"L Piccio","year":"2010","unstructured":"Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010;67(6):707\u201314. https:\/\/doi.org\/10.1001\/archneurol.2010.99.","journal-title":"Arch Neurol"},{"issue":"1","key":"1182_CR124","doi-asserted-by":"publisher","first-page":"fcae021","DOI":"10.1093\/braincomms\/fcae021","volume":"6","author":"F van Puijfelik","year":"2024","unstructured":"van Puijfelik F, Blok KM, Klein Kranenbarg RAM, et al. Ocrelizumab associates with reduced cerebrospinal fluid B and CD20(dim) CD4(+) T cells in primary progressive multiple sclerosis. Brain Commun. 2024;6(1):fcae021. https:\/\/doi.org\/10.1093\/braincomms\/fcae021.","journal-title":"Brain Commun."},{"key":"1182_CR125","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.msard.2019.02.013","volume":"30","author":"P Bhargava","year":"2019","unstructured":"Bhargava P, Wicken C, Smith MD, et al. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement. Mult Scler Relat Disord. 2019;30:136\u201340. https:\/\/doi.org\/10.1016\/j.msard.2019.02.013.","journal-title":"Mult Scler Relat Disord."},{"key":"1182_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105344","volume":"81","author":"S Dahal","year":"2024","unstructured":"Dahal S, Allette YM, Naunton K, Harrison DM. A pilot trial of ocrelizumab for modulation of meningeal enhancement in multiple sclerosis. Mult Scler Relat Disord. 2024;81: 105344. https:\/\/doi.org\/10.1016\/j.msard.2023.105344.","journal-title":"Mult Scler Relat Disord."},{"issue":"2","key":"1182_CR127","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s11481-020-09931-w","volume":"16","author":"A Carnasciali","year":"2021","unstructured":"Carnasciali A, Amoriello R, Bonechi E, et al. T cell delivery of nanoparticles-bound anti-CD20 monoclonal antibody: successful B cell depletion in the spinal cord during experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2021;16(2):376\u201389. https:\/\/doi.org\/10.1007\/s11481-020-09931-w.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"6","key":"1182_CR128","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.3390\/ijms23063172","volume":"23","author":"S Tacke","year":"2022","unstructured":"Tacke S, Chunder R, Schropp V, Urich E, Kuerten S. Effects of a fully humanized type II anti-CD20 monoclonal antibody on peripheral and CNS B cells in a transgenic mouse model of multiple sclerosis. Int J Mol Sci. 2022;23(6):3172. https:\/\/doi.org\/10.3390\/ijms23063172.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1182_CR129","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000381524","volume":"38","author":"V Goede","year":"2015","unstructured":"Goede V, Klein C, Stilgenbauer S. Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-Hodgkin\u2019s lymphomas: a glycoengineered type II CD20 antibody. Oncol Res Treat. 2015;38(4):185\u201392. https:\/\/doi.org\/10.1159\/000381524.","journal-title":"Oncol Res Treat."},{"issue":"3","key":"1182_CR130","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000975","volume":"8","author":"J Roodselaar","year":"2021","unstructured":"Roodselaar J, Zhou Y, Leppert D, Hauser AE, Urich E, Anthony DC. Anti-CD20 disrupts meningeal B-cell aggregates in a model of secondary progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;8(3): e975. https:\/\/doi.org\/10.1212\/NXI.0000000000000975.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"11","key":"1182_CR131","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080533","volume":"8","author":"CP Mao","year":"2013","unstructured":"Mao CP, Brovarney MR, Dabbagh K, Birnb\u00f6ck HF, Richter WF, Del Nagro CJ. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. PLoS ONE. 2013;8(11): e80533. https:\/\/doi.org\/10.1371\/journal.pone.0080533.","journal-title":"PLoS ONE"},{"key":"1182_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.814064","volume":"13","author":"JB Torres","year":"2022","unstructured":"Torres JB, Roodselaar J, Sealey M, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol. 2022;13: 814064. https:\/\/doi.org\/10.3389\/fimmu.2022.814064.","journal-title":"Front Immunol"},{"key":"1182_CR133","unstructured":"European Medicines Agency. Ocrevus assessment report. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/ocrevus-h-c-004043-x-0039-epar-assessment-report-variation_en.pdf. Accessed 12 Mar 2025."},{"key":"1182_CR134","unstructured":"Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq). Prescribing information. Genentech; 2024. https:\/\/www.gene.com\/download\/pdf\/ocrevus_zunovo_prescribing.pdf. Accessed 12 Mar 2025."},{"issue":"6","key":"1182_CR135","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1917246.","journal-title":"N Engl J Med"},{"key":"1182_CR136","unstructured":"Sangha KS, Jakubecz C, Maynard M, et al. Real-world predictors of hypogammaglobulinemia in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: the REPLACE-MS study. Presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting; 29 May-1 Jun 2024; Nashville, TN, USA. Abstract 9657."},{"key":"1182_CR137","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ddtec.2016.07.009","volume":"20","author":"J Paterson","year":"2016","unstructured":"Paterson J, Webster CI. Exploiting transferrin receptor for delivering drugs across the blood-brain barrier. Drug Discov Today Technol. 2016;20:49\u201352. https:\/\/doi.org\/10.1016\/j.ddtec.2016.07.009.","journal-title":"Drug Discov Today Technol"},{"key":"1182_CR138","unstructured":"Genentech. Our Pipeline | RG6035 BrainShuttleTM CD20. https:\/\/www.gene.com\/medical-professionals\/pipeline\/rg6035-brainshuttletm-cd20#rg6035-brainshuttletm-cd20-multiple-sclerosis. Accessed 12 Mar 2025."},{"issue":"5","key":"1182_CR139","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.2021011994","volume":"141","author":"L Falchi","year":"2023","unstructured":"Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood. 2023;141(5):467\u201380. https:\/\/doi.org\/10.1182\/blood.2021011994.","journal-title":"Blood"},{"key":"1182_CR140","unstructured":"Columvi (glofitamab-gxbm). Prescribing information. Genentech; 2023. https:\/\/www.gene.com\/download\/pdf\/columvi_prescribing.pdf. Accessed 6 Mar 2025."},{"issue":"7","key":"1182_CR141","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","volume":"20","author":"RE Kontermann","year":"2015","unstructured":"Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20(7):838\u201347. https:\/\/doi.org\/10.1016\/j.drudis.2015.02.008.","journal-title":"Drug Discov Today"},{"key":"1182_CR142","unstructured":"Blincyto (blinatumomab). Prescribing information. Amgen Inc.; 2024. https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/blincyto\/blincyto_pi_hcp_english.pdf. Accessed 6 Mar 2025."},{"issue":"6","key":"1182_CR143","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci L, Hagen M, Rothe T, et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat Med. 2024;30(6):1593\u2013601. https:\/\/doi.org\/10.1038\/s41591-024-02964-1.","journal-title":"Nat Med"},{"key":"1182_CR144","unstructured":"Lunsumio (mosunetuzumab-axgb). Prescribing information. Genentech; 2024. https:\/\/www.gene.com\/download\/pdf\/lunsumio_prescribing.pdf. Accessed 6 Mar 2025."},{"key":"1182_CR145","unstructured":"Epkinly (epcoritamab-bysp). Prescribing information. Genmab US, Inc.; 2024. https:\/\/www.genmab-pi.com\/prescribing-information\/epkinly-pi.pdf. Accessed 6 Mar 2025."},{"issue":"8","key":"1182_CR146","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585\u2013608. https:\/\/doi.org\/10.1038\/s41573-019-0028-1.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1182_CR147","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40259-019-00400-2","volume":"34","author":"Q Zhao","year":"2020","unstructured":"Zhao Q. Bispecific antibodies for autoimmune and inflammatory diseases: clinical progress to date. BioDrugs. 2020;34(2):111\u20139. https:\/\/doi.org\/10.1007\/s40259-019-00400-2.","journal-title":"BioDrugs"},{"issue":"4","key":"1182_CR148","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002907","volume":"9","author":"U Blache","year":"2023","unstructured":"Blache U, Tretbar S, Koehl U, Mougiakakos D, Fricke S. CAR T cells for treating autoimmune diseases. RMD Open. 2023;9(4): e002907. https:\/\/doi.org\/10.1136\/rmdopen-2022-002907.","journal-title":"RMD Open"},{"key":"1182_CR149","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.coph.2021.05.005","volume":"59","author":"M Wehrli","year":"2021","unstructured":"Wehrli M, Maus MV. New CARs on and off the road: challenges and new developments in CAR-T cell therapy. Curr Opin Pharmacol. 2021;59:116\u201326. https:\/\/doi.org\/10.1016\/j.coph.2021.05.005.","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"1182_CR150","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"issue":"8","key":"1182_CR151","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N Engl J Med. 2024;390(8):687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917.","journal-title":"N Engl J Med"},{"issue":"6","key":"1182_CR152","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach F, Richter J, Pfeffer LK, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024;5(6):550-8.e2. https:\/\/doi.org\/10.1016\/j.medj.2024.03.002.","journal-title":"Med"},{"key":"1182_CR153","unstructured":"NIH. https:\/\/clinicaltrials.gov\/. Accessed 12 Mar 2025."},{"issue":"2","key":"1182_CR154","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/cells13020146","volume":"13","author":"C Lonez","year":"2024","unstructured":"Lonez C, Breman E. Allogeneic CAR-T therapy technologies: has the promise been met? Cells. 2024;13(2):146. https:\/\/doi.org\/10.3390\/cells13020146.","journal-title":"Cells"},{"issue":"6295","key":"1182_CR155","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353(6295):179\u201384. https:\/\/doi.org\/10.1126\/science.aaf6756.","journal-title":"Science"},{"issue":"9","key":"1182_CR156","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","volume":"41","author":"S Oh","year":"2023","unstructured":"Oh S, Mao X, Manfredo-Vieira S, et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat Biotechnol. 2023;41(9):1229\u201338. https:\/\/doi.org\/10.1038\/s41587-022-01637-z.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"1182_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e19763","volume":"9","author":"M Sahlolbei","year":"2023","unstructured":"Sahlolbei M, Azangou-Khyavy M, Khanali J, et al. Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: an in-vitro study. Heliyon. 2023;9(9): e19763. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e19763.","journal-title":"Heliyon."},{"issue":"1","key":"1182_CR158","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-019-0752-3","volume":"12","author":"S Ayyappan","year":"2019","unstructured":"Ayyappan S, Maddocks K. Novel and emerging therapies for B cell lymphoma. J Hematol Oncol. 2019;12(1):82. https:\/\/doi.org\/10.1186\/s13045-019-0752-3.","journal-title":"J Hematol Oncol"},{"issue":"15","key":"1182_CR159","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.3390\/cancers15153886","volume":"15","author":"P Gogia","year":"2023","unstructured":"Gogia P, Ashraf H, Bhasin S, Xu Y. Antibody-drug conjugates: a review of approved drugs and their clinical level of evidence. Cancers (Basel). 2023;15(15):3886. https:\/\/doi.org\/10.3390\/cancers15153886.","journal-title":"Cancers (Basel)."},{"issue":"4","key":"1182_CR160","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1124\/pharmrev.123.001084","volume":"76","author":"Z Huang","year":"2024","unstructured":"Huang Z, Braunstein Z, Chen J, et al. Precision medicine in rheumatic diseases: unlocking the potential of antibody-drug conjugates. Pharmacol Rev. 2024;76(4):579\u201398. https:\/\/doi.org\/10.1124\/pharmrev.123.001084.","journal-title":"Pharmacol Rev"},{"issue":"4","key":"1182_CR161","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood.2021014663","volume":"140","author":"E Calabretta","year":"2022","unstructured":"Calabretta E, Hamadani M, Zinzani PL, Caimi P, Carlo-Stella C. The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma. Blood. 2022;140(4):303\u20138. https:\/\/doi.org\/10.1182\/blood.2021014663.","journal-title":"Blood"},{"issue":"5","key":"1182_CR162","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","volume":"97","author":"E Crickx","year":"2020","unstructured":"Crickx E, Weill JC, Reynaud CA, Mahevas M. Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives. Kidney Int. 2020;97(5):885\u201393. https:\/\/doi.org\/10.1016\/j.kint.2019.12.025.","journal-title":"Kidney Int"},{"issue":"1","key":"1182_CR163","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","volume":"19","author":"DH Whittam","year":"2019","unstructured":"Whittam DH, Tallantyre EC, Jolles S, et al. Rituximab in neurological disease: principles, evidence and practice. Pract Neurol. 2019;19(1):5\u201320. https:\/\/doi.org\/10.1136\/practneurol-2018-001899.","journal-title":"Pract Neurol"},{"issue":"2","key":"1182_CR164","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1053\/j.seminhematol.2010.01.001","volume":"47","author":"SA Beers","year":"2010","unstructured":"Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47(2):107\u201314. https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.001.","journal-title":"Semin Hematol"}],"updated-by":[{"DOI":"10.1007\/s40263-025-01187-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01182-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01182-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01182-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T06:21:18Z","timestamp":1746685278000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01182-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":164,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1182"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01182-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40263-025-01187-3","asserted-by":"object"}]},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"16 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected. Figure 5A is corrected in the PDF version.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40263-025-01187-3","URL":"https:\/\/doi.org\/10.1007\/s40263-025-01187-3","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for\u00a0the\u00a0open access fee, medical writing and editorial support was provided by TG Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Data sharing is not applicable to this article, as no data sets were generated or analyzed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"B.A.A.C. has received personal compensation for consulting from Alexion, Autobahn, Avotres, Biogen, Boston Pharma, EMD Serono, Hexal\/Sandoz, Horizon, Immunic AG, Kyverna, Neuron23, Novartis, Sanofi, Siemens, and TG Therapeutics and received research support from Genentech and Kyverna. J.R.B. has served as a consultant for Celgene\/BMS, Cellevolve, EMD Serono\/Merck, Genentech\/Roche, Genzyme, Gilead, Janssen\/J&J, Morphic, NeuVIR, Novartis, Population Bio, Sanofi, Takeda, and TG Therapeutics. He has served on the scientific advisory or data safety monitoring board for MAPI and Excision BioTherapeutics. He has served for Neurology Reviews and WebMD. B.G. has received consulting fees from Alexion, Novartis, EMD Serono, Horizon Therapeutics\/Amgen, Genentech\/Roche, Signant, IQVIA, Sandoz, Sanofi\/Genzyme, TG Therapeutics, Cycle Pharma, Arialys, Clene, Syneos, and PRIME Education. He has received grant funding from NIH, Anokion, and Regeneron. He serves as an unpaid member of the board of the Siegel Rare Neuroimmune Association. He has equity in Clene and GenrAb. He receives royalties from UpToDate.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Drafting and critical revision of the manuscript for important intellectual content: B.A.C.C., J.R.B., and B.G. All authors have read and approved the final submitted manuscript and agree to be accountable for the work.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}